These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11899073)

  • 1. DNA vaccines.
    Reyes-Sandoval A; Ertl HC
    Curr Mol Med; 2001 May; 1(2):217-43. PubMed ID: 11899073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technical and regulatory hurdles for DNA vaccines.
    Donnelly J; Berry K; Ulmer JB
    Int J Parasitol; 2003 May; 33(5-6):457-67. PubMed ID: 12782047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccination: a potential weapon against infection and cancer.
    Stevenson FK; Rosenberg W
    Vox Sang; 2001 Jan; 80(1):12-8. PubMed ID: 11339062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current progress of DNA vaccine studies in humans.
    Lu S; Wang S; Grimes-Serrano JM
    Expert Rev Vaccines; 2008 Mar; 7(2):175-91. PubMed ID: 18324888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.
    Kraynyak KA; Bodles-Brakhop A; Bagarazzi M
    Curr Top Microbiol Immunol; 2017; 405():55-78. PubMed ID: 25682101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
    Wozniak TM; Ryan AA; Triccas JA; Britton WJ
    Infect Immun; 2006 Jan; 74(1):557-65. PubMed ID: 16369012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy.
    Haupt K; Roggendorf M; Mann K
    Exp Biol Med (Maywood); 2002 Apr; 227(4):227-37. PubMed ID: 11910045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
    Pavlenko M; Leder C; Pisa P
    Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technologies for enhanced efficacy of DNA vaccines.
    Saade F; Petrovsky N
    Expert Rev Vaccines; 2012 Feb; 11(2):189-209. PubMed ID: 22309668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
    Rice J; Elliott T; Buchan S; Stevenson FK
    J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccines: an historical perspective and view to the future.
    Liu MA
    Immunol Rev; 2011 Jan; 239(1):62-84. PubMed ID: 21198665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
    Ni J; Schirrmacher V; Fournier P
    Vaccine; 2010 Oct; 28(42):6891-900. PubMed ID: 20709006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial toxin's DNA vaccine serves as a strategy for the treatment of cancer, infectious and autoimmune diseases.
    Behzadi E; Halabian R; Hosseini HM; Fooladi AAI
    Microb Pathog; 2016 Nov; 100():184-194. PubMed ID: 27671283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system.
    Meerak J; Wanichwecharungruang SP; Palaga T
    Vaccine; 2013 Jan; 31(5):784-90. PubMed ID: 23228812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to DNA vaccines.
    Kowalczyk DW; Ertl HC
    Cell Mol Life Sci; 1999 May; 55(5):751-70. PubMed ID: 10379361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.